Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : Seqens
Deal Size : Undisclosed
Deal Type : Agreement
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
Details : ProtheraCytes is an autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack.
Product Name : Protheracytes
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 20, 2025
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Seqens
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : BioCardia
Deal Size : Undisclosed
Deal Type : Collaboration
CellProthera and BioCardia Collaborate on Phase II ProtheraCytes™ Trial for AMI
Details : The collaboration aims to support the advancement of the mid-stage clinical trial product ProtheraCytes, which is being evaluated for the treatment of acute myocardial infarction led by CellProthera.
Product Name : Protheracytes
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 07, 2024
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : BioCardia
Deal Size : Undisclosed
Deal Type : Collaboration